Boxer, L
When examining a composite cardio outcomes endpoint (death from CV disease, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), the ELIXA trial suggested that GLP-1s did not increase cardiovascular event risk (hazard ratio of 1.02)
3 Graphical abstract Table 1 Baseline demographics of patients with a diagnosis of T2DM receiving SGLT2is versus GLP1-RAs Values are presented as number (%) or meanstandard deviation
In signaling pathways, post-treatment showed a decrease in the enrichment of the PPAR signaling pathway, but an increase in the intestinal immune network for IgA production and the serotonergic synapse. Moreover, changes were noticed in the expression of specific metabolites
Constipation emerges in about 25% of users, resulting from slowed intestinal motility
Often used cyclically (e.g., 3 months on, 1 month off)